Dear Ladies and Gentlemen,
The strategy of Sopharma Group in recent years is aimed at strengthening the integration between the various businesses of the Group, so that even greater opportunities and synergies can be realized. The Group’s strategy in the Healthcare sector is to work on a business model based on vertical integration between the manufacturer, wholesaler and retailer with a focus on building a strong relationship with the end customer.
These two important strategic directions lead the companies in the Group to a new stage of development, which a requires a change in the way of management.
Regarding the above, we inform you that the Board of Directors of Sopharma Trading AD decides to change the managing and representative bodies of the company.
Mr. Ognian Donev, Chairman of Board of Directors of Sopharma Trading AD, was elected for CEO. The decision of the Board of Directors will be registered in the Commercial Register and Register of non-profit legal entities. Mr. Donev will replace Mr. Dimitar Dimitrov, the current CEO of Sopharma Trading AD. The company expresses its gratitude to Mr. Dimitrov for the results achieved in his capacity as a Chief Executive Officer.
We also notify you that the Board of Directors of Sopharma Trading AD determines and authorizes Mr. Boris Borisov for procurator of Sopharma Trading AD. The change was registered in the Commercial Register and Register of non-profit legal entities, Registry agency with number 20210920154132 dated September 20, 2021.